| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Advances and perspectives in human and mouse embryonic stem cell bioprocessing
|
Oh, Steve K.W.
|
|
2008
|
21-22 |
4 |
p. e125-e130
nvt p.
|
artikel
|
| 2 |
Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists
|
Kansy, Manfred
|
|
2004
|
21-22 |
4 |
p. 349-355
7 p.
|
artikel
|
| 3 |
Advances in virtual screening
|
Muegge, Ingo
|
|
2006
|
21-22 |
4 |
p. 405-411
7 p.
|
artikel
|
| 4 |
Approaches to Scaffold Hopping
|
Lloyd, David G.
|
|
2013
|
21-22 |
4 |
p. e451-e452
nvt p.
|
artikel
|
| 5 |
Automation and robotics in ADME screening
|
Saunders, Kenneth C.
|
|
2004
|
21-22 |
4 |
p. 373-380
8 p.
|
artikel
|
| 6 |
Building in molecular diversity for targeted libraries
|
Sheppard, David W.
|
|
2013
|
21-22 |
4 |
p. e461-e466
nvt p.
|
artikel
|
| 7 |
Caco-2 replace or refine?
|
Ungell, Anna-Lena B.
|
|
2004
|
21-22 |
4 |
p. 423-430
8 p.
|
artikel
|
| 8 |
Chemical diversity and biological activity
|
Schuffenhauer, Ansgar
|
|
2006
|
21-22 |
4 |
p. 387-395
9 p.
|
artikel
|
| 9 |
Cheminformatics and drug discovery
|
Oprea, Tudor I.
|
|
2006
|
21-22 |
4 |
p. 355-356
2 p.
|
artikel
|
| 10 |
Computational prediction of drug toxicity: the case of mutagenicity and carcinogenicity
|
Benigni, Romualdo
|
|
2004
|
21-22 |
4 |
p. 457-463
7 p.
|
artikel
|
| 11 |
Conformations and 3D pharmacophore searching
|
Schwab, Christof H.
|
|
2010
|
21-22 |
4 |
p. e245-e253
nvt p.
|
artikel
|
| 12 |
Contents
|
|
|
2004
|
21-22 |
4 |
p. i-
1 p.
|
artikel
|
| 13 |
Contents
|
|
|
2005
|
21-22 |
4 |
p. i-
1 p.
|
artikel
|
| 14 |
Contents
|
|
|
2008
|
21-22 |
4 |
p. i-
1 p.
|
artikel
|
| 15 |
C(X)CR in silico: Computer-aided prediction of chemokine receptor–ligand interactions
|
Roumen, L.
|
|
2012
|
21-22 |
4 |
p. e281-e291
nvt p.
|
artikel
|
| 16 |
De novo design – hop(p)ing against hope
|
Schneider, Gisbert
|
|
2013
|
21-22 |
4 |
p. e453-e460
nvt p.
|
artikel
|
| 17 |
De-peptidising protein–protein interactions – big jobs for small molecules
|
Fayne, Darren
|
|
2013
|
21-22 |
4 |
p. e467-e474
nvt p.
|
artikel
|
| 18 |
Derivation, maintenance and cryostorage of human embryonic stem cells
|
Holm, Frida
|
|
2008
|
21-22 |
4 |
p. e131-e137
nvt p.
|
artikel
|
| 19 |
Docking compared to 3D-pharmacophores: the scoring function challenge
|
Hein, Michael
|
|
2010
|
21-22 |
4 |
p. e229-e236
nvt p.
|
artikel
|
| 20 |
3D pharmacophore elucidation and virtual screening
|
Wolber, Gerhard
|
|
2010
|
21-22 |
4 |
p. e203-e204
nvt p.
|
artikel
|
| 21 |
3D pharmacophores as tools for activity profiling
|
Schuster, Daniela
|
|
2010
|
21-22 |
4 |
p. e205-e211
nvt p.
|
artikel
|
| 22 |
Editorial
|
|
|
2005
|
21-22 |
4 |
p. 303-304
2 p.
|
artikel
|
| 23 |
Epigenetic remodeling and stem cells
|
Altun, Gulsah
|
|
2008
|
21-22 |
4 |
p. e139-e142
nvt p.
|
artikel
|
| 24 |
Focused chemistry from annotated libraries
|
Balakin, Konstantin V.
|
|
2006
|
21-22 |
4 |
p. 397-403
7 p.
|
artikel
|
| 25 |
‘Fuzziness’ in pharmacophore-based virtual screening and de novo design
|
Klenner, Alexander
|
|
2010
|
21-22 |
4 |
p. e237-e244
nvt p.
|
artikel
|
| 26 |
Grid-derived structure-based 3D pharmacophores and their performance compared to docking
|
Cross, Simon
|
|
2010
|
21-22 |
4 |
p. e213-e219
nvt p.
|
artikel
|
| 27 |
High throughput protein crystallography: Developments in crystallisation, data collection and data processing
|
O’Reilly, Marc
|
|
2006
|
21-22 |
4 |
p. 451-456
6 p.
|
artikel
|
| 28 |
History of 3D pharmacophore searching: commercial, academic and open-source tools
|
Van Drie, John H.
|
|
2010
|
21-22 |
4 |
p. e255-e262
nvt p.
|
artikel
|
| 29 |
Hit and lead identification: Integrated technology-based approaches
|
Goodnow Jr, Robert A.
|
|
2006
|
21-22 |
4 |
p. 367-375
9 p.
|
artikel
|
| 30 |
Imaging approaches for monitoring chemotherapy
|
Bacharach, Stephen L.
|
|
2005
|
21-22 |
4 |
p. 329-334
6 p.
|
artikel
|
| 31 |
Imaging studies for evaluating gene therapy in translational research
|
Peñuelas, Iván
|
|
2005
|
21-22 |
4 |
p. 335-343
9 p.
|
artikel
|
| 32 |
Imaging studies in drug development: Parkinson's disease
|
Brooks, David J.
|
|
2005
|
21-22 |
4 |
p. 317-321
5 p.
|
artikel
|
| 33 |
Imaging technologies in drug development: Anxiety and depression
|
Rabiner, Eugenii A.
|
|
2005
|
21-22 |
4 |
p. 323-327
5 p.
|
artikel
|
| 34 |
Information systems for surrogate biomarkers
|
Hehenberger, Michael
|
|
2005
|
21-22 |
4 |
p. 369-373
5 p.
|
artikel
|
| 35 |
Inhibition of PDZ domain-mediated interactions
|
Grillo-Bosch, Dolors
|
|
2013
|
21-22 |
4 |
p. e531-e540
nvt p.
|
artikel
|
| 36 |
Inhibitors of protein–protein interactions: New methodologies to tackle this challenge
|
Silvian, Laura
|
|
2013
|
21-22 |
4 |
p. e509-e515
nvt p.
|
artikel
|
| 37 |
In silico prediction of drug safety: despite progress there is abundant room for improvement
|
Egan, William J.
|
|
2004
|
21-22 |
4 |
p. 381-387
7 p.
|
artikel
|
| 38 |
‘In silico’ simulations to assess the ‘in vivo’ consequences of ‘in vitro’ metabolic drug–drug interactions
|
Rostami-Hodjegan, Amin
|
|
2004
|
21-22 |
4 |
p. 441-448
8 p.
|
artikel
|
| 39 |
In silico target fishing: Predicting biological targets from chemical structure
|
Jenkins, Jeremy L.
|
|
2006
|
21-22 |
4 |
p. 413-421
9 p.
|
artikel
|
| 40 |
Integrating disease knowledge and technology to deliver protein targets and biomarkers into drug discovery projects
|
Fehniger, Thomas E.
|
|
2005
|
21-22 |
4 |
p. 345-351
7 p.
|
artikel
|
| 41 |
Integration of virtual and physical screening
|
Fara, Dan C.
|
|
2006
|
21-22 |
4 |
p. 377-385
9 p.
|
artikel
|
| 42 |
Intestinal and blood–brain drug transport: beyond involvement of a single transport function
|
Lennernäs, Hans
|
|
2004
|
21-22 |
4 |
p. 417-422
6 p.
|
artikel
|
| 43 |
Lead- and drug-like compounds: the rule-of-five revolution
|
Lipinski, Christopher A.
|
|
2004
|
21-22 |
4 |
p. 337-341
5 p.
|
artikel
|
| 44 |
Lipophilicity – beyond octanol/water: a short comparison of modern technologies
|
Hartmann, Thorsten
|
|
2004
|
21-22 |
4 |
p. 431-439
9 p.
|
artikel
|
| 45 |
Livers cells derived from human embryonic stem cells
|
Andersson, Tommy B.
|
|
2008
|
21-22 |
4 |
p. e143-e147
nvt p.
|
artikel
|
| 46 |
Mass spectrometry-based methods for biomarker detection and analysis
|
von Neuhoff, Nils
|
|
2005
|
21-22 |
4 |
p. 361-367
7 p.
|
artikel
|
| 47 |
Metabolic screening in vitro: metabolic stability, CYP inhibition and induction
|
Riley, Robert J.
|
|
2004
|
21-22 |
4 |
p. 365-372
8 p.
|
artikel
|
| 48 |
Molecular crime scene investigation – dusting for fingerprints
|
Bajorath, Jürgen
|
|
2013
|
21-22 |
4 |
p. e491-e498
nvt p.
|
artikel
|
| 49 |
Molecular topology – dissimilar similarities
|
Galvez, Jorge
|
|
2013
|
21-22 |
4 |
p. e475-e481
nvt p.
|
artikel
|
| 50 |
NMR in the analysis of functional chemokine interactions and drug discovery
|
Ziarek, Joshua J.
|
|
2012
|
21-22 |
4 |
p. e293-e299
nvt p.
|
artikel
|
| 51 |
Peptidylarginine deiminases: physiological function, interaction with chemokines and role in pathology
|
Moelants, Eva A.V.
|
|
2012
|
21-22 |
4 |
p. e261-e280
nvt p.
|
artikel
|
| 52 |
PET studies in drug development: Methodological considerations
|
Cunningham, Vincent J.
|
|
2005
|
21-22 |
4 |
p. 311-315
5 p.
|
artikel
|
| 53 |
Physicochemical profiling: overview of the screens
|
Kerns, E.H.
|
|
2004
|
21-22 |
4 |
p. 343-348
6 p.
|
artikel
|
| 54 |
Physiology-based pharmacokinetic modeling: ready to be used
|
Schmitt, Walter
|
|
2004
|
21-22 |
4 |
p. 449-456
8 p.
|
artikel
|
| 55 |
Predicting the intestinal absorption potential of hits and leads
|
Hämäläinen, M.D.
|
|
2004
|
21-22 |
4 |
p. 397-405
9 p.
|
artikel
|
| 56 |
Prediction of blood–brain barrier permeation in drug discovery from in vivo, in vitro and in silico models
|
Abbott, N. Joan
|
|
2004
|
21-22 |
4 |
p. 407-416
10 p.
|
artikel
|
| 57 |
Prediction of human clearance (CL) and volume of distribution (VD)
|
Keldenich, Jörg
|
|
2004
|
21-22 |
4 |
p. 389-395
7 p.
|
artikel
|
| 58 |
Probing structural adaptivity at PPI interfaces with small molecules
|
Wilson, Christopher G.
|
|
2013
|
21-22 |
4 |
p. e501-e508
nvt p.
|
artikel
|
| 59 |
Protein pathway analysis in Clinical Proteomics using protein microarrays
|
Geho, David H.
|
|
2005
|
21-22 |
4 |
p. 353-359
7 p.
|
artikel
|
| 60 |
Proteomic approaches in drug discovery
|
Veenstra, Timothy D.
|
|
2006
|
21-22 |
4 |
p. 433-440
8 p.
|
artikel
|
| 61 |
Proteomics in antitumor research
|
Fontana, Simona
|
|
2006
|
21-22 |
4 |
p. 441-449
9 p.
|
artikel
|
| 62 |
Rational design of LEDGINs as first allosteric integrase inhibitors for the treatment of HIV infection
|
Desimmie, Belete A.
|
|
2013
|
21-22 |
4 |
p. e517-e522
nvt p.
|
artikel
|
| 63 |
Scaffold variations in amine warhead of histamine H3 receptor antagonists
|
Wingen, Kerstin
|
|
2013
|
21-22 |
4 |
p. e483-e489
nvt p.
|
artikel
|
| 64 |
Screening for the role of transporters in hepatic and renal drug handling
|
Masereeuw, Rosalinde
|
|
2004
|
21-22 |
4 |
p. 357-364
8 p.
|
artikel
|
| 65 |
Small molecule inhibitors of the HIV-1 virulence factor, Nef
|
Smithgall, Thomas E.
|
|
2013
|
21-22 |
4 |
p. e523-e529
nvt p.
|
artikel
|
| 66 |
Small-molecule modulation of protein–protein interactions
|
Ottmann, Christian
|
|
2013
|
21-22 |
4 |
p. e499-e500
nvt p.
|
artikel
|
| 67 |
Small molecules modulation of 14-3-3 protein–protein interactions
|
Mori, Mattia
|
|
2013
|
21-22 |
4 |
p. e541-e547
nvt p.
|
artikel
|
| 68 |
Stem cell reprogramming: generation of patient-specific stem cells by somatic cell nuclear reprogramming
|
Simonsson, Stina
|
|
2008
|
21-22 |
4 |
p. e117-e124
nvt p.
|
artikel
|
| 69 |
Stem cells
|
Carney, Steve L.
|
|
2008
|
21-22 |
4 |
p. e105-e106
nvt p.
|
artikel
|
| 70 |
Strategies for 3D pharmacophore-based virtual screening
|
Seidel, Thomas
|
|
2010
|
21-22 |
4 |
p. e221-e228
nvt p.
|
artikel
|
| 71 |
Target, chemical and bioactivity databases – integration is key
|
Oprea, Tudor I.
|
|
2006
|
21-22 |
4 |
p. 357-365
9 p.
|
artikel
|
| 72 |
Targeting chemokine–glycan interactions: the CellJammer® technology platform
|
Trinker, Martin U.
|
|
2012
|
21-22 |
4 |
p. e253-e259
nvt p.
|
artikel
|
| 73 |
Targeting chemokines and chemokine receptors with antibodies
|
Klarenbeek, Alex
|
|
2012
|
21-22 |
4 |
p. e237-e244
nvt p.
|
artikel
|
| 74 |
Targeting the chemokine receptor system
|
Smit, Martine J.
|
|
2012
|
21-22 |
4 |
p. e227-e228
nvt p.
|
artikel
|
| 75 |
Techniques for rational design
|
Kubinyi, Hugo
|
|
2006
|
21-22 |
4 |
p. 423-424
2 p.
|
artikel
|
| 76 |
The enabling technologies needed for PET-based molecular imaging to support drug development
|
Jones, Terry
|
|
2005
|
21-22 |
4 |
p. 305-309
5 p.
|
artikel
|
| 77 |
The fragment-approach: An update
|
Bartoli, Sandra
|
|
2006
|
21-22 |
4 |
p. 425-431
7 p.
|
artikel
|
| 78 |
Therapeutic targeting of chemokine receptors by small molecules
|
Wijtmans, Maikel
|
|
2012
|
21-22 |
4 |
p. e229-e236
nvt p.
|
artikel
|
| 79 |
The scaffold hopping potential of pharmacophores
|
Hessler, Gerhard
|
|
2010
|
21-22 |
4 |
p. e263-e269
nvt p.
|
artikel
|
| 80 |
Unnatural amino acids for the study of chemokine receptor structure and dynamics
|
Siderius, Marco
|
|
2012
|
21-22 |
4 |
p. e301-e313
nvt p.
|
artikel
|
| 81 |
Viral and non-viral gene delivery and its role in pluripotent stem cell engineering
|
Kane, Nicole M.
|
|
2008
|
21-22 |
4 |
p. e107-e115
nvt p.
|
artikel
|
| 82 |
Why and how to find neutraligands targeting chemokines?
|
Galzi, Jean-Luc
|
|
2012
|
21-22 |
4 |
p. e245-e251
nvt p.
|
artikel
|
Tijdschrift beschrijving